Product Description
Mechanisms of Action: Sebum Production Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acne Vulgaris
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03127956 |
DRM01B-ACN05 | P3 |
Completed |
Acne Vulgaris |
2018-04-27 |
2019-03-21 |
Patient Enrollment|Treatments |
|
NCT03073486 |
DRM01B-ACN04 | P3 |
Completed |
Acne Vulgaris |
2017-12-21 |
2019-03-21 |
||
NCT03028363 |
DRM01B-ACN03 | P3 |
Completed |
Acne Vulgaris |
2017-11-28 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/19/2019 |
News Article |
Global Acne Market Spotlight 2017-2018 & 2019-2026 - ResearchAndMarkets.com |
